{"product_id":"fosun-bcg-matrix","title":"Fosun International Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCurious about Fosun International's strategic product portfolio? This glimpse into their BCG Matrix reveals how their offerings stack up as Stars, Cash Cows, Dogs, or Question Marks. Unlock the full potential of this analysis by purchasing the complete report for actionable insights and a clear roadmap to optimizing Fosun's market position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHenlius's Innovative Biopharmaceuticals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHenlius, a key player within Fosun International's portfolio, stands out as a star in the biopharmaceutical sector. Its innovative products, like HANSIZHUANG, are driving significant growth. \u003c\/p\u003e\n\u003cp\u003eHANSIZHUANG's EU marketing approval in early 2025 is a major achievement, signaling strong potential in the rapidly expanding oncology market. This success highlights Henlius's competitive strength and its capacity for international reach. \u003c\/p\u003e\n\u003cp\u003eThe European launch of HANSIZHUANG points to a promising high-growth path and an increasing market share in sophisticated medical treatments. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFosun Kairos CAR-T Cell Therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFosun International's acquisition of full control of Fosun Kairos, a pioneer in CAR-T cell therapy, underscores a strategic push into high-potential, advanced medical treatments. This move signals a strong belief in the future of cellular immunotherapy for cancer.\u003c\/p\u003e\n\u003cp\u003eCAR-T therapy represents a significant investment in a rapidly expanding and innovative sector of healthcare. Fosun Kairos is poised to be a key player in this evolving market, with potential for substantial future growth and market leadership.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClub Med's Mountain Resorts Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eClub Med's mountain resorts are a shining star within Fosun International's portfolio, experiencing a robust 20% surge in business volume during 2024. This impressive growth, coupled with strong forward bookings for 2025, highlights a significant uptick in demand for both winter ski and summer mountain getaways. \u003c\/p\u003e\n\u003cp\u003eThis segment is riding the wave of increasing consumer appetite for premium, experiential travel, a trend that Club Med is expertly leveraging. The company's strategic focus on an upmarket transformation, alongside its expansion into key markets like the Asia-Pacific region, is clearly paying dividends, solidifying its position as a high-growth area with an expanding market share. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFosun Pharma's High-Value Medical Devices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFosun Pharma's strategic emphasis on high-value medical devices, coupled with a robust innovation pipeline, solidifies its position as a star within Fosun International's portfolio. This segment is demonstrating impressive financial performance.\u003c\/p\u003e\n\u003cp\u003eThe company's commitment to research and development, alongside effective commercialization strategies, is driving significant growth. This focus is translating into tangible financial results.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrong Operating Cash Flow:\u003c\/strong\u003e The medical devices segment reported a substantial operating cash flow growth of 31.13% year-on-year in 2024, underscoring its market strength.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Penetration:\u003c\/strong\u003e This growth indicates increasing penetration in a dynamic and expanding market, a key indicator for star performers.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFuture Growth Potential:\u003c\/strong\u003e Continued investment in R\u0026amp;D and commercialization efforts are expected to further enhance market share and profitability in the coming periods.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFosun RZ Capital's Cutting-Edge Tech Investments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFosun RZ Capital, Fosun International's dedicated venture capital arm, is a key player in identifying and nurturing disruptive technologies. Their strategy focuses on high-growth, high-tech startups in global emerging markets and innovation hubs, aiming to secure Fosun's future market leadership in rapidly evolving sectors.\u003c\/p\u003e\n\u003cp\u003eThese investments are characterized by significant growth potential and a strategic focus on capturing future market leaders. While their current market shares may vary, the underlying objective is to cultivate these early-stage companies into dominant forces within their respective industries.\u003c\/p\u003e\n\u003cp\u003eFosun RZ Capital’s portfolio reflects a forward-looking approach, targeting sectors poised for substantial expansion. For instance, in 2023, they were active in areas like artificial intelligence, biotechnology, and new energy, aligning with global trends and Fosun's broader strategic interests.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eFocus on Emerging Tech:\u003c\/strong\u003e Investments in AI, biotech, and new energy.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGlobal Reach:\u003c\/strong\u003e Active in innovation hubs across North America, Europe, and Asia.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEarly-Stage Support:\u003c\/strong\u003e Nurturing startups with high growth potential.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Alignment:\u003c\/strong\u003e Positioning Fosun for future market leadership in expanding sectors.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFosun's Stars: Growth in Pharma, Travel, and Tech!\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHenlius, a biopharmaceutical company under Fosun International, is a star performer, particularly with its innovative oncology drug, HANSIZHUANG. The drug's EU marketing approval in early 2025, coupled with its European launch, signals significant growth potential and increasing market share in the competitive oncology sector.\u003c\/p\u003e\n\u003cp\u003eFosun Pharma's medical devices segment is also a star, demonstrating robust financial performance driven by a strong innovation pipeline and effective commercialization. In 2024, this segment saw a substantial 31.13% year-on-year growth in operating cash flow, indicating strong market penetration and future profitability.\u003c\/p\u003e\n\u003cp\u003eClub Med's mountain resorts are another star, experiencing a 20% surge in business volume in 2024 and showing strong forward bookings for 2025. This growth is attributed to the increasing demand for premium, experiential travel and Club Med's successful upmarket transformation and market expansion.\u003c\/p\u003e\n\u003cp\u003eFosun RZ Capital, Fosun International's venture capital arm, invests in high-growth, high-tech startups, identifying future market leaders. Their investments in sectors like AI, biotechnology, and new energy in 2023 reflect a strategy to capture emerging market trends and secure future growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eBusiness Unit\u003c\/th\u003e\n\u003cth\u003eCategory\u003c\/th\u003e\n\u003cth\u003eKey Highlights (2024\/Early 2025)\u003c\/th\u003e\n\u003cth\u003eGrowth Indicator\u003c\/th\u003e\n\u003cth\u003eMarket Position\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHenlius\u003c\/td\u003e\n\u003ctd\u003eBiopharmaceuticals\u003c\/td\u003e\n\u003ctd\u003eHANSIZHUANG EU marketing approval (early 2025), European launch\u003c\/td\u003e\n\u003ctd\u003eHigh Growth Potential\u003c\/td\u003e\n\u003ctd\u003eExpanding Market Share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFosun Pharma (Medical Devices)\u003c\/td\u003e\n\u003ctd\u003eMedical Devices\u003c\/td\u003e\n\u003ctd\u003e31.13% YoY operating cash flow growth (2024)\u003c\/td\u003e\n\u003ctd\u003eStrong Operating Cash Flow\u003c\/td\u003e\n\u003ctd\u003eIncreasing Market Penetration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClub Med\u003c\/td\u003e\n\u003ctd\u003eHospitality\/Travel\u003c\/td\u003e\n\u003ctd\u003e20% business volume surge (2024), strong 2025 bookings\u003c\/td\u003e\n\u003ctd\u003eRobust Demand\u003c\/td\u003e\n\u003ctd\u003eExpanding Market Share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFosun RZ Capital\u003c\/td\u003e\n\u003ctd\u003eVenture Capital\u003c\/td\u003e\n\u003ctd\u003eInvestments in AI, Biotech, New Energy (2023)\u003c\/td\u003e\n\u003ctd\u003eHigh Growth Potential\u003c\/td\u003e\n\u003ctd\u003eCultivating Future Market Leaders\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eThis BCG Matrix overview provides clear descriptions and strategic insights for Fosun International's Stars, Cash Cows, Question Marks, and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA clear BCG Matrix visualizes Fosun's portfolio, easing the pain of understanding complex business unit performance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClub Med's Overall Premium Resorts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClub Med's premium resorts, a key asset within Fosun's portfolio, continue to be a robust cash cow. In 2024, the brand saw a notable 7% increase in business volume, underscoring its enduring appeal and market dominance in the premium all-inclusive sector. This consistent performance is driven by successful upscale repositioning and high occupancy rates.\u003c\/p\u003e\n\u003cp\u003eThe strong and stable cash flow generated by Club Med is crucial for Fosun, enabling strategic investments in other business units. This mature brand acts as a reliable financial engine, supporting the group's broader growth initiatives and diversification efforts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFosun Insurance Portugal\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFosun Insurance Portugal stands as a prime example of a Cash Cow within Fosun International's portfolio.  Its consistent, high-quality growth is evident, with total gross written premiums hitting around EUR6,172 million in 2024.\u003c\/p\u003e\n\u003cp\u003eOperating in a mature financial services sector, Fosun Insurance Portugal leverages its robust market standing and a growing international presence, which now accounts for 29.8% of its business. This translates into substantial and dependable cash flows.\u003c\/p\u003e\n\u003cp\u003eThis segment acts as a vital, stable financial bedrock, underpinning Fosun's wider investment strategies and providing a reliable source of capital for other ventures.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAtlantis Sanya\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAtlantis Sanya, a premier integrated resort in China, demonstrated robust performance throughout 2024. It achieved a remarkable average occupancy rate of 89.6%, reflecting strong demand and its established position in the market.\u003c\/p\u003e\n\u003cp\u003eThis high occupancy translates into significant business volume, underscoring its role as a consistent cash generator for Fosun International. Operating within China's mature domestic tourism sector, Atlantis Sanya leverages its strong brand recognition and premium services to maintain high profitability.\u003c\/p\u003e\n\u003cp\u003eThe resort's consistent income stream solidifies its status as a Cash Cow within Fosun's portfolio, contributing stable financial returns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYuyuan Commercial and Consumer Brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eYuyuan, a cornerstone of Fosun International's strategy, operates as a significant cash cow. Its extensive portfolio of well-established commercial and consumer brands thrives in mature markets, benefiting from high brand awareness and loyal customer bases. This stability translates into consistent profit generation and robust cash flow for Fosun.\u003c\/p\u003e\n\u003cp\u003eIn 2023, Yuyuan's contribution was substantial, with its diverse operations underpinning Fosun International's financial strength. For instance, the Yuyuan Bazaar, a key asset, reported impressive visitor numbers and retail sales growth, demonstrating the enduring appeal and profitability of its core businesses. This consistent performance solidifies Yuyuan's position as a vital cash-generating entity within the group.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eBrand Strength:\u003c\/strong\u003e Yuyuan's brands benefit from decades of market presence and consumer trust, ensuring consistent demand.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Maturity:\u003c\/strong\u003e Operating in established markets allows for predictable revenue streams and efficient operations.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCash Flow Generation:\u003c\/strong\u003e The stable profits generated by Yuyuan's businesses provide significant cash flow to Fosun International.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Importance:\u003c\/strong\u003e As one of Fosun's four core subsidiaries, Yuyuan plays a critical role in the group's overall financial health and investment capacity.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFosun Pharma's Established Drug Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFosun Pharma's established drug portfolio represents a significant cash cow for Fosun International. These mature products, including generics and essential medicines, command substantial market share in well-developed regions. Their consistent demand generates stable, predictable revenue with high profit margins, contributing reliably to the company's overall cash flow.\u003c\/p\u003e\n\u003cp\u003eThese established drugs are crucial for maintaining Fosun Pharma's financial stability. They provide a predictable income stream, allowing the company to fund research and development for its innovative pipeline. For instance, in 2023, Fosun Pharma reported revenue of approximately RMB 42.4 billion, with a significant portion likely attributable to its established product lines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Dominance:\u003c\/strong\u003e Key established drugs hold leading positions in their respective therapeutic areas.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStable Revenue:\u003c\/strong\u003e Predictable sales from these products ensure consistent cash generation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHigh Profitability:\u003c\/strong\u003e Mature products typically benefit from lower R\u0026amp;D costs and optimized manufacturing, leading to strong profit margins.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCash Flow Support:\u003c\/strong\u003e These cash cows provide the financial foundation for investment in future growth areas.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFosun's Financial Powerhouses: Consistent Profits \u0026amp; Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFosun International's Cash Cows are its mature, high-performing businesses that generate substantial and consistent profits. These entities are vital for funding other strategic initiatives within the conglomerate.  They benefit from strong market positions and established brand loyalty, ensuring a steady inflow of capital.\u003c\/p\u003e\n\u003cp\u003eThese businesses, like Club Med and Fosun Insurance Portugal, demonstrate consistent growth and profitability. In 2024, Club Med saw a 7% business volume increase, while Fosun Insurance Portugal reported EUR6,172 million in gross written premiums. Atlantis Sanya maintained an 89.6% occupancy rate, further highlighting their stable cash-generating capabilities.\u003c\/p\u003e\n\u003cp\u003eThe financial strength derived from these cash cows is instrumental for Fosun International's overall financial health and its ability to pursue new investments and diversification strategies. They represent the bedrock of the group's financial stability.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eBusiness Unit\u003c\/td\u003e\n\u003ctd\u003e2024 Performance Indicator\u003c\/td\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eSignificance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClub Med\u003c\/td\u003e\n\u003ctd\u003eBusiness Volume\u003c\/td\u003e\n\u003ctd\u003e+7%\u003c\/td\u003e\n\u003ctd\u003eRobust cash generation from premium resorts.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFosun Insurance Portugal\u003c\/td\u003e\n\u003ctd\u003eGross Written Premiums\u003c\/td\u003e\n\u003ctd\u003eEUR 6,172 million\u003c\/td\u003e\n\u003ctd\u003eStable and high-quality growth in financial services.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAtlantis Sanya\u003c\/td\u003e\n\u003ctd\u003eAverage Occupancy Rate\u003c\/td\u003e\n\u003ctd\u003e89.6%\u003c\/td\u003e\n\u003ctd\u003eConsistent income stream from a leading integrated resort.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYuyuan\u003c\/td\u003e\n\u003ctd\u003eVisitor Numbers \u0026amp; Retail Sales\u003c\/td\u003e\n\u003ctd\u003eGrowth reported in 2023\u003c\/td\u003e\n\u003ctd\u003eStrong brand awareness and loyal customer base driving profits.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFosun Pharma (Established Drugs)\u003c\/td\u003e\n\u003ctd\u003eRevenue Contribution\u003c\/td\u003e\n\u003ctd\u003eSignificant portion of RMB 42.4 billion (2023)\u003c\/td\u003e\n\u003ctd\u003eStable revenue and high margins from mature pharmaceutical products.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview = Final Product\u003c\/span\u003e\u003cbr\u003eFosun International BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe preview of the Fosun International BCG Matrix you are currently viewing is the complete and final document you will receive upon purchase. This means the in-depth analysis, clear visualizations, and strategic insights into Fosun's business units are exactly as presented, ready for your immediate use. You can confidently download this version knowing it's unwatermarked and fully formatted for professional application in your strategic planning or presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55674509885817,"sku":"fosun-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/fosun-bcg-matrix.png?v=1755790664","url":"https:\/\/portersfiveforce.com\/products\/fosun-bcg-matrix","provider":"Porter's Five Forces","version":"1.0","type":"link"}